Publicado

2019-01-01

Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano

From psychiatric disorders to antibiotic therapy: repositioning of chlorpromazine as an antibacterial agent

DOI:

https://doi.org/10.15446/rcciquifa.v48n1.80062

Palabras clave:

Reposicionamento de fármacos, fenotiazina, bombas de efluxo, resis¬tência bacteriana, Staphylococccus aureus, Mycobacterium tuberculosis (pt)
Drug repositioning, phenothiazine, efflux pumps, bacterial resistance, Staphylococccus aureus, Mycobacterium tuberculosis (en)

Descargas

Autores/as

  • William Gustavo Lima Universidade Federal de São João del Rei (UFSJ) - Laboratório de Microbiologia Médica
  • Maria Cristina Ramos-Alves Universidade Federal de São João del-Rei (UFSJ)
  • Adriana Cristina Soares Universidade Federal de São João del-Rei (UFSJ) - Laboratório de Farmacologia da dor e inflamação
O alarmante aumento na taxa de resistência aos antibióticos põe em check à eficácia da terapia antibacteriana futura. Em contrapartida, as indústrias farmacêuticas negligenciam os investimentos em pesquisa e desenvolvimento de novos fármacos antimicrobianos em virtude de questões financeiras, legais e farmacológicas. Assim sendo, o reposicionamento de agentes disponíveis clinicamente torna-se uma promissora ferramenta para tentar driblar o desinteresse das indústrias. O fármaco antipsicótico clorpromazina (CPZ) destaca-se por possuir uma ampla faixa de atividade antibacteriana, a qual cobre desde patógenos Gram-positivos e Gram-negativos, até as micobactérias. A atividade antibacteriana é independente do perfil de susceptibilidade do microrganismo, sendo ela mantida mesmo em cepas altamente resistentes aos antibióticos. Alguns estudos mostram que mesmo nas concentrações clinicamente disponíveis no plasma (entre 0,1-0,5 μg/mL), a CPZ é capaz de matar Staphylococcus aureus e Mycobacterium tuberculosis dentro dos macrófagos. Em adição, estudos clínicos têm revelado os benefícios do uso da CPZ na terapia de suporte para pacientes com infecções em curso. Em conclusão, a CPZ pode eventualmente ser direcionada ao arsenal terapêutico antimicrobiano, especialmente no manejo das infecções causadas por microrganismos intracelulares com fenótipo multirresistente.
The substantial increase in the antibiotic resistance brings on an alarm to the future of the antibiotic therapy. However, the pharmaceutical industry has been neglecting its investments in new drug research and development, mainly because of the pharmacologic, financial and legal factors. Therefore, the drug repositioning of clinic available agents become a promising tool to bypass the lack of interest of the pharmaceutical industry. A drug used to treat psychoses, the Chlorpromazine (CPZ), stands out as a large spectrum antibiotic, which covers Gram-positive and Gram -negative bacteria, and also mycobacteria. Its antibacterial activity is not related to microorganism susceptibility profile, and it could be maintained even on strains highly resistant to the conventional antibiotics. Studies point out that even on serum concentrations clinically available, the CPZ can eliminate Staphylococcus aureus and Mycobacterium tuberculosis inside of macrophages. In addition, clinical trials have revealed its benefits on support therapy for patients suffering from active infections. As a result, the CPZ could be used as an optional antibiotic therapy, especially in case of infections due to intracellular microorganisms with multidrug resistance phenotype.

Referencias

B. Spellberg, J.H. Powers, E.P. Brass, L.G. Miller, J.E. Edwards, Trends in Antimicrobial Drug Development: Implications for the Future, Clin. Infect. Dis., 38, 1279 (2004).

World Health Organization (WHO). The top 10 causes of death: The 10 leading causes of death by country income group. URL: http://www.who.int/mediacentre/factsheets/fs310/en/index.html>, consultado em maio de 2016.

World Health Organization (WHO). Antimicrobial resistance: Global report on surveillance. URL:http://www.who.int/drugresistance/documents/AMR_report_Web_slide_set.pdf?ua=1, acessado em maio de 2016.

J. O´Neill, Tackling drug-resistant infections globally: final report and recommendations, Review on Antimicrobial Resistance (2016).

L.M. Barros, J.N.B. Castro, J.A. Caetano, R.A.N. Moreira, F.G.F. Pereira, N.M. Frota, et al., Prevalência de micro-organismo e sensibilidade antimicrobiana de infecções hospitalares em unidade de terapia intensiva de hospital público no Brasil, Rev. Ciênc. Farm. Básica Apl., 33, 429 (2012).

L.D. Sanchez-Velazquez, S.P.L. Rosales, M.S.R. Fausto, the burden of nosocomial infection in the intensive care unit: effects on organ failure, mortality and costs. A Nested case-control study, Arch. Med. Res., 37, 370 (2006).

G.H. Talbolt, J. Bradley, J.E. Edwards, D. Gilbert, M. Scheld, J.G. Bartlett, Bad bugs need drugs: An update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America, Clin. Infect. Dis., 42, 657 (2006).

H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert D, L.B. Rice, et al., Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America, Clin. Infect. Dis., 48, 1 (2009).

U. Theuretzbacher, Future antibiotics scenarios: is the tide starting to turn?, Int. J. Antimicrob. Agents, 34, 15 (2009).

J.A. Dimasi, R.W. Hansen, H.G. Grabowski, The price of innovation: new estimates of drug development costs, J. Health. Econ., 22, 151 (2003).

J.E. Kristiansen, L. Amaral, The potential management of resistant infections with non-antibiotics, J. Antimicrob. Chemother., 40, 319 (1997).

K. Ahmed, H.V. Shaw, A. Koval, V.L. Katanaev, A second WNT for old drugs: drug repositioning against WNT-dependent cancers, Cancers (Basel), 8, E66 (2016).

L. Amaral, M. Viveiros, J.Molnar, Antimicrobial activity of phenothiazines, In Vivo, 18, 725 (2004).

J.A. Crowle, G.S. Douvas, M.H. May, Chlorpromazine: a drug potentially useful for treating mycobacterial infections, Chemotherapy, 38, 410 (1992).

M.M. Kristiansen, C. Leandro, D. Ordway, M. Martins, M. Viveiros, T. Pacheco, et al., Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro, Int. J. Antimicrob. Agents, 22, 250 (2003).

M.M. Kristiansen, C. Leandro, D. Ordway, M. Martins, M. Viveiros, T. Pacheco, et al., Thioridazine reduces resistance of methicillin-resistant Staphylococcus aureus by inhibiting a reserpine-sensitive efflux pump, In Vivo, 20, 361 (2006).

J. Molnár, A. Hevér, I. Fakla, J. Fischer, I. Ocsovski , A. Aszalós, Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells, Anticancer Res., 17, 481 (1997).

G.W. Kaatz, V.V. Moudgal, S.M. Seo, J.E. Kristiansen, Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus, Antimicrob. Agents Chemother., 47, 719 (2003).

J.E. Kristiansen, The antimicrobial activity of psychotherapeutic drugs and stereo-isomeric analogues, Dan. Med. Bull, 37, 165 (1990).

L. Amaral, J. Kristiansen, V. Lorian, Synergic effect of chlorpromazine on the activity of some antibiotics, J. Antimicrob. Chemother., 30, 556 (1992).

S. Baugh, A.S. Ekanayaka, L.J. Piddock, M.A. Webber, Loss of or inhibition of all multidrug resistance efflux pumps of Salmonella enterica serovar Typhimurium results in impaired ability to form a biofilm, J. Antimicrob. Chemother.,67, 2409 (2012).

P. Charpentier, P. Gailliot, R. Jacob, J. Gaudechon, P. Buisson, Recherches sur les diméthylaminopropyl-N phénothiazines substituées, Comptes rendus de l´Académie des sciences, 235, 59 (1952).

W.W. Shen, A history of antipsychotic drug development, Compr. Psychiatry, 40, 407 (1999).

M.E. Lickey, B. Gordon, Medicamentos para las enfermedades mentales, Labor: Barcelona, 78 (1986).

World Health Organization (WHO). WHO model list of essential medicines. URL: apps.who.int/iris/bitstream/10665/93142/1/EML˙18˙eng.pdf?ua=1. 18th, consultado em abril de 2013.

B.G. Katzung, “Farmacologia: básica e clínica”, Guanabara Koogan Eds., Rio de Janeiro, 2005, vol. 9, p. 1216.

F.G. Graeff, Antipsicóticos. em: “Drogas psicotrópicas e seu modo de ação”;, E.P.U. Eds., São Paulo, 1989, vol. 1, p. 110.

F.G. Graeff, F.S. Guimarães, “Fundamentos de psicofarmacologia”, Atheneu Eds., São Paulo, 1999, vol. 2, p. 288.

R.C.B. Silva, Esquizofrenia: uma revisão, Psicologia USP, 17, 263 (2006).

P.K. Gillman, Serotonin syndrome: history and risk, Fundam. Clin. Pharmacol., 12, 482 (1998).

P.K. Gillman, The serotonin syndrome and its treatment, J. Psychopharmacol., 13, 100 (1999).

J.D. Wildin, B.J. Pleuvry, G.E. Mawer, Impairment of psychomotor function at modest plasmaconcentrations of carbamazepine after administration of liquid suspension to naive subjects, Br. J. Clin. Pharmacol, 35, 14 (1993).

G. Wik, Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood, J. Endocrinol., 144, 425 (1995).

L.J. Lipka, C.M. Lathers, J. Roberts, Does chlorpromazine produce cardiac arrhythmia via the central nervous system?, J. Clin. Pharmacol., 28, 968 (1988).

S.Y. Choi, Y.H. Kim, Y.K. Lee, K.T. Kim, Chlorpromazine inhibits store-operated calcium entry and subsequent noradrenaline secretion in PC12 cells, Br. J. Pharmacol. 132, 411 (2001).

N. Ghosh, U. Chattopadhyay, Enhancement of immune response by phenothiazine administration, In Vivo, In Vivo, 7, 435 (1993).

T. Lialiaris, A. Pantazaki, E. Sivridis, D. Mourelatos, Chlorpromazine-induced damage on nucleic acids: acombined cytogenetic and biochemical study, Mutat. Res., 265, 155 (1992).

A. Martins, L. Machado, S. Costa, P. Cerca, G. Spengler, M. Viveiros, et al., Role of calcium in the efflux system of Escherichia coli, Int. J. Antimicrob. Agents., 37, 410 (2011).

C.M. Menezes, K. Kirchgatter, S.M. Di Santi, C. Savalli, F.G. Monteiro, G.A.Paula, et al., In vitro chloroquine resistance modulation study on fresh isolates of Brazilian Plasmodium falciparum: intrinsic antimalarial activity of phenothiazine drugs, Mem. Inst. Oswaldo Cruz, 97, 1033 (2002).

J. Guan, D.E. Kyle, L. Gerena, Q. Zhang, W.K. Milhous, A.J. Lin, Design, synthesis and evaluation of new chemosensitizers in multi-drug-resistant Plasmodium falciparum, J. Med. Chem., 45, 2741 (2002).

M. Kalkanidis, N. Klonis, L. Tilley, L.W. Deady, Novel phenothiazine antimalarials: synthesis, antimalarial activity, and inhibition of the formation of beta-haematin, Biochem. Pharmacol., 63, 833 (2002).

R.D. Pearson, A.A. Manian, D. Hall, J.L. Harcus, E.L. Hewlett, Antileishmanial activity of chlorpromazine, Antimicrob. Agents Chemother., 25, 571 (1984).

J.D. Berman, L.S. Lee, Activity of oral drugs against Leishmania tropica in human macrophages in vitro, Am. J. Trop. Med. Hyg., 32, 947 (1983).

L. Galgóczy, A. Bácsi, M. Homa, M. Virágh, T. Papp, C. Vágvölgyi, In vitro antifungal activity of phenothiazines and their combination with amphotericin B against different Candida species, Mycoses, 54, 737 (2011).

R.G. Vitale, J. Afeltra, J.F. Meis, P.E. Verweij, Activity and post antifungal effect of chlorpromazine and trifluopherazine against Aspergillus, Scedosporium and zygomycetes, Mycoses, 50, 270 (2007).

J.H. Kim, S.Y. Jung, Y.J. Lee, K.J. Song, D. Kwon, K. Kim, et al., Effect of therapeutic chemical agents in vitro and on experimental meningoencephalitis due to Naegleria fowleri, Antimicrob. Agents Chemother., 52, 4010 (2008).

Y. Shimizu, Modification of host cell membrane after herpes simplex virus infection, Arch. Gesamte. Virusforsch., 33, 338 (1971).

H. Libikowa, D. Stancek, V. Wiedermann, J. Hasto, S. Breier, Psychopharmacy and electroconvulsive therapy in relation to viral antibodies and interferon. Experimental and clinical study, Arch. Immunol. Ther. Exp. Warsz, 25, 641 (1977).

S.Z. Hirschman, E. Garfinkel, Inhibition of hepatitis B DNA polymerase by intercalating agents, Nature, 271, 681 (1978).

W. Bohn, G. Rutter, H. Hohenberg, K. Mannweiler, Inhibition of measles virus budding by phenothiazines, Virology, 15, 44 (1983).

M.J. Schlesinge, D. Cahill, Verapamil and chlorpromazine inhibit the budding of Sindbis and vesicular stomatitis viruses from infected chicken embryo fibroblasts, Virology, 168, 187 (1989).

K.M. Nugent, J.D. Shanley, Verapamil inhibits influenza A virus replication, Arch. Virol., 81, 163 (1984).

H. Hirai, S. Takeda, S. Natori, K. Sekimizu, Inhibition of SV40 DNA replication in vitro by chlorpromazine, Biol. Pharm. Bull, 16, 565 (1993).

N.A. Candurra, L. Maskin, E.B. Damonte, Inhibition of arenavirus multiplication in vitro by phenotiazines, Antiviral Res., 31, 149 (1996).

W.J. Atwood, A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus ( JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukoencephalopathy, J. Neurovirol., 7, 307 (2001).

J.E. Kristiansen, Experiments to illustrate the effect of chlorpromazine on the permeability of the bacterial cell wall, Acta Pathol. Microbiol. Scand. B., 87, 317 (1979).

D. Ordway, M. Viveiros, C. Leandro, M. Jorge Arroz, J. Molnar, J.E. Kristiansen, et al., Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations, J. Infect. Chemother., 8, 227 (2002).

H. Nehme, P. Saulnier, A. A. Ramadan, V.Cassisa, C. Guillet, M. Eveillard, A. Umerska, Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity, PLoS One, 13, e0189950 (2018).

R. Kong, O.H. Kang, Y.S. Seo, S.H. Mun, T. Zhou, D.W. Shin, et al., The inhibition effect of Chlorpromazine against the b-lactam resistance of MRSA, Asian Pacific J. Trop. Med., 9, 542 (2016).

M. Rahbar, H. Mehrgan, S. Hadji-Nejad, Enhancement of vancomycin activity by phenothiazines against vancomycin-resistant Enterococcus faecium in vitro, Basic Clin. Pharmacol. Toxicol., 107, 676 (2010).

O. Hendricks, T.S. Butterworth, J.E. Kristiansen, The in-vitro antimicrobial effect of non-antibiotics and putative inhibitors of efflux pumps on Pseudomonas aeruginosa and Staphylococcus aureus, Int. J. Antimicrob. Agents., 22, 262 (2003).

K. Dudley, X. Liu, S. De Haan. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst. Rev., 13, 4 (2017).

L. Amaral, J.E. Kristiansen, M. Viveiros, J. Atouguia, Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy, J. Antimicrob. Chemother., 47, 505 (2000).

L. Amaral, J.E. Kristiansen, Phenothiazines: potential management of Creutzfeldt- Jakob disease and its variants, Int. J. Antimicrob. Agents, 18, 411 (2001).

J. Molnár, Y. Mándi, J. Király, Antibacterial effect of some phenothiazine compounds and R-factor elimination by chlorpromazine, Acta Microbiol. Acad. Sci. Hung., 23, 45 (1976).

J.E Kristiansen, I. Mortensen, Antibacterial effect of four phenothiazines, Pharmacol. Toxicol., 60, 100 (1987).

L. Amaral, J. Kristiansen, V. Lorian, Synergic effect of chlorpromazine on the activity of some antibiotics, J. Antimicrob. Chemother., 30, 556 (1992).

H.D. Coutinho, J.G. Costa, E.O Lima, V.S. Falcão-Silva, J.P. Siqueira-Júnior, Enhancement of the antibiotic activity against a multiresistant Escherichia coli by Mentha arvensis L. and chlorpromazine, Chemotherapy, 54, 328 (2008).

H.D. Coutinho, J.G. Costa, E.O Lima, V.S. Falcão-Silva, J.P. Siqueira-Júnior, In vitro interference of Hyptis martiusii Benth. & chlorpromazine against an aminoglycoside- resistant Escherichia coli, Indian. J. Med. Res., 129, 566 (2009).

H.D. Coutinho, J.G. Costa, E.O Lima, V.S. Falcão-Silva, J.P. Siqueira-Júnior, Increasing of the aminoglicosyde antibiotic activity against a multidrug-resistant E. coli by Turnera ulmifolia L. and chlorpromazine, Biol. Res. Nurs., 11, 332 (2010).

A.M. Bailey, I.T. Paulsen, L.J. Piddock, RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine, Antimicrob. Agents Chemother., 52, 3604 (2008).

J.E. Kristiansen, J. Blom, Effect of chlorpromazine on the ultrastructure of Staphylococcus aureus, Acta Pathol. Microbiol. Scand B., 89, 399 (1981).

L. Amaral, V. Lorian, Effects of chlorpromazine on the cell envelope proteins of Escherichia coli, Antimicrob. Agents Chemother., 35, 1923 (1991).

B.G. Spratt, A.B. Pardee, Penicillin-binding proteins and cell shape in E. coli, Nature, 254, 516 (1975).

A.H. Delcour, Outer membrane permeability and antibiotic resistance, Biochim. Biophys. Acta., 1794, 808 (2009).

J.W. Brown, The Ribonuclease P Database, Nucleic Acids Res., 27, 314 (1999).

W.U. Shiying, M. Guanzhong, A. L. Kirsebom, Inhibition of Bacterial RNase P RNA by Phenothiazine Derivatives, Biomolecules, 6, 38 (2016).

L. Amaral, J.E. Kristiansen, L.S. Abebe, W. Millett, Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis, J. Antimicrob. Chemother., 38, 1049 (1996).

M.V. Reddy, G. Nadadhur, P.R. Gangadharam, In-vitro intracellular antimycobacterial activity of trifluoperazine, J. Antimicrob. Chemother., 37, 196 (1996).

D.V. Gadre, V. Talwar, In vitro susceptibility testing of Mycobacterium tuberculosis strains to trifluoperazine, J. Chemother., 11, 203 (1999).

P. Ratnakar, S.P Rao, P. Sriramara, P.S Murthy, Structure–antitubercular activity relationship of phenothiazine-type calmodulin antagonists, Int. Clin. Psychopharmacol., 10, 39 (1995).

A.B. Bate, J.H. Kalin, E.M. Fooksman, E.L. Amorose, C.M. Price, H.M. Williams, et al., Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives, Bioorg. Med. Chem. Lett., 17, 1346 (2007).

M.V. Bettencourt, S. Bosne-David, L. Amaral, Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis, Int. J. Antimicrob. Agents, 16, 69 (2000).

D.V. Gadre, V. Talwar, H.C. Gupta, P.S. Murthy, Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis, Int. Clin. Psychopharmacol., 13, 129 (1998).

T. Yano, L.S. Li, E. Weinstein, J.S Teh, H. Rubin, Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2), J. Biol. Chem., 281, 11456 (2006).

B.M. Saunders, W.J. Britton, Life and death in the granuloma: immunopathology of tuberculosis, Immunol. Cell Biol., 85, 103 (2007).

M. Martins, Z. Schelz, A. Martins, J. Molnar, G. Hajos, Z. Riedl, et al., In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis, Int. J. Antimicrob. Agents, 29, 338 (2007).

D. Ordway, M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, M. Martins et al., Clinical concentrations of thioridazine kill intracellular multidrugresistant Mycobacterium tuberculosis, Antimicrob. Agents Chemother., 47, 917 (2003).

E.A. Weinstein, T. Yano, L.S. Li, D. Avarbock, A. Avarbock, D. Helm, et al., Inhibitors of type II NADH: menaquinone oxidoreductase represents a class of antitubercular drugs. Proc. Natl. Acad. Sci. USA, 102, 4548 (2005).

L. Amaral, M. Viveiros, J.E. Kristiansen, ‘Non-antibiotics’: alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries, Curr. Drug Targets, 7, 887 (2006).

L. Amaral, M. Martins, M. Viveiros, Enhanced killing of intracellular multidrug- resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps, J. Antimicrob. Chemother., 59, 1237 (2007).

L. Amaral, J.E. Kristiansen, Phenothiazines: an alternative to conventional therapy for the initial management of suspect multidrug resistance tuberculosis. A call for studies, Int. J. Antimicrob. Agents, 14, 173 (2000).

P.R Kodavanti, W.R. Mundy, H.A. Tilson, G.J. Harry, Effects of selected neuroactive chemicals on calcium transporting systems in rat cerebellum and on survival of cerebellar granule cells, Fundam. Appl. Toxicol., 21, 308 (1993).

M. Chitsaz, M.H. Brown, The role played by drug efflux pumps in bacterial multidrug resistance, Essays Biochem., 61, 127 (2017).

L. Zhibin, C. Yumei, C. Yufan, C. Yingying, Z. Lianhui, RND efflux pump and its interrelationship with quorum sensing system, Yi Chuan., 38, 894 (2016).

C. Costa, P.J. Dias, I. Sá-Correia, M.C. Teixeira, MFS multidrug transporters in pathogenic fungi: do they have real clinical impact?, Front. Physiol., 5, 197 (2014).

H. Lage, ABC-transporters: implications on drug resistance from microorganisms to human cancers, Int. J. Antimicrob. Agents, 22, 188 (2003).

Y.J. Chung, M.H. Saie Jr, SMR-type multidrug resistance pumps, Curr. Opin. Drug Discov. Devel., 4, 237 (2001).

J. Handzlik, A. Matys, K. Kieć-Kononowicz, Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus, Antibiotics (Basel), 2, 28 (2013).

Y. Miyamoto, D.F. Balkovetz, V. Ganapathy, T. Iwatsubo, M. Hanano, F.H. Leibach, Effects of phenothiazines on the Na+-H+ exchanger of the brush-border membrane from the proximal small intestine of the rabbit, J. Pharmacol. Exp. Ther., 245, 823 (1988).

X. Roucou, S. Manon, M. Guérin, Investigations of the inhibitory effect of propranolol, chlorpromazine, quinine, and dicyclohexylcarbodiimide on the swelling of yeast mitochondria in potassium acetate. Evidences for indirect effects mediated by the lipid phase, J. Bioenerg. Biomembr., 27, 353 (1995).

M. Toth, H. Frase, N.T. Antunes, C.A. Smith, S.B. Vakulenko, Crystal structure and kinetic mechanism of aminoglycoside phosphotransferase-2’’-Iva, Protein. Sci., 19, 1565 (2010).

K.T. Madsen, M.N. Skov, S. Gill, M. Kemp, Virulence Factors Associated with Enterococcus Faecalis Infective Endocarditis: A Mini Review. Open Microbiol. J., 11, 1 (2017).

J. Molnar, I. Mucsi, P. Kasa, Inhibition of the adhesion of E. coli on cultured human epithelial cells in the presence of promethazine or imipramine, Zentralbl. Bakteriol. Mikrobiol. Hyg., 254, 3883 (1983).

J. Molnar, K. Csiszar, E. Czirok, E. Szollosy, Adhesion properties of E. coli cells in the presence of promethazine, Zentralbl. Bakteriol. Mikrobiol. Hyg., 266, 276 (1987).

Cómo citar

APA

Lima, W. G., Ramos-Alves, M. C. & Soares, A. C. (2019). Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano. Revista Colombiana de Ciencias Químico-Farmacéuticas, 48(1), 5–28. https://doi.org/10.15446/rcciquifa.v48n1.80062

ACM

[1]
Lima, W.G., Ramos-Alves, M.C. y Soares, A.C. 2019. Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano. Revista Colombiana de Ciencias Químico-Farmacéuticas. 48, 1 (ene. 2019), 5–28. DOI:https://doi.org/10.15446/rcciquifa.v48n1.80062.

ACS

(1)
Lima, W. G.; Ramos-Alves, M. C.; Soares, A. C. Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano. Rev. Colomb. Cienc. Quím. Farm. 2019, 48, 5-28.

ABNT

LIMA, W. G.; RAMOS-ALVES, M. C.; SOARES, A. C. Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano. Revista Colombiana de Ciencias Químico-Farmacéuticas, [S. l.], v. 48, n. 1, p. 5–28, 2019. DOI: 10.15446/rcciquifa.v48n1.80062. Disponível em: https://revistas.unal.edu.co/index.php/rccquifa/article/view/80062. Acesso em: 22 mar. 2026.

Chicago

Lima, William Gustavo, Maria Cristina Ramos-Alves, y Adriana Cristina Soares. 2019. «Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano». Revista Colombiana De Ciencias Químico-Farmacéuticas 48 (1):5-28. https://doi.org/10.15446/rcciquifa.v48n1.80062.

Harvard

Lima, W. G., Ramos-Alves, M. C. y Soares, A. C. (2019) «Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano», Revista Colombiana de Ciencias Químico-Farmacéuticas, 48(1), pp. 5–28. doi: 10.15446/rcciquifa.v48n1.80062.

IEEE

[1]
W. G. Lima, M. C. Ramos-Alves, y A. C. Soares, «Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano», Rev. Colomb. Cienc. Quím. Farm., vol. 48, n.º 1, pp. 5–28, ene. 2019.

MLA

Lima, W. G., M. C. Ramos-Alves, y A. C. Soares. «Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano». Revista Colombiana de Ciencias Químico-Farmacéuticas, vol. 48, n.º 1, enero de 2019, pp. 5-28, doi:10.15446/rcciquifa.v48n1.80062.

Turabian

Lima, William Gustavo, Maria Cristina Ramos-Alves, y Adriana Cristina Soares. «Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano». Revista Colombiana de Ciencias Químico-Farmacéuticas 48, no. 1 (enero 1, 2019): 5–28. Accedido marzo 22, 2026. https://revistas.unal.edu.co/index.php/rccquifa/article/view/80062.

Vancouver

1.
Lima WG, Ramos-Alves MC, Soares AC. Dos distúrbios psiquiátricos à antibioticoterapia: reposicionamento da clorpromazina como agente antibacteriano. Rev. Colomb. Cienc. Quím. Farm. [Internet]. 1 de enero de 2019 [citado 22 de marzo de 2026];48(1):5-28. Disponible en: https://revistas.unal.edu.co/index.php/rccquifa/article/view/80062

Descargar cita

CrossRef Cited-by

CrossRef citations11

1. Horlando Carlota da Silva, Antonio Linkoln Alves Borges Leal, Mauro Macedo de Oliveira, Humberto Medeiros Barreto, Henrique Douglas Melo Coutinho, Hélcio Silva dos Santos, Gilvandete Maria Pinheiro Santiago, Thiago Sampaio de Freitas, Igor Kleber Campos Lima, Alexandre Magno Rodrigues Teixeira, Carlos Emídio Sampaio Nogueira. (2020). Structural characterization, antibacterial activity and NorA efflux pump inhibition of flavonoid fisetinidol. South African Journal of Botany, 132, p.140. https://doi.org/10.1016/j.sajb.2020.03.023.

2. Ana Luíza A.R. Martin, Raimundo Luiz Silva Pereira, Janaína Esmeraldo Rocha, Pablo A.M. Farias, Thiago S. Freitas, Francisco Rodrigo de Lemos Caldas, Fernando G. Figueredo, Nadghia Figueiredo Leite Sampaio, Jaime Ribeiro-Filho, Irwin Rose de Alencar Menezes, Guilherme Andrade Brancaglion, Daniela Carvalho de Paulo, Diogo T. Carvalho, Micheline Azevedo Lima, Henrique D.M. Coutinho, Marta M.F. Fonteles. (2023). In vitro and in silico evidences about the inhibition of MepA efflux pump by coumarin derivatives. Microbial Pathogenesis, 182, p.106246. https://doi.org/10.1016/j.micpath.2023.106246.

3. Luiz Jardelino de Lacerda Neto, Andreza Guedes Barbosa Ramos, Thiago Sampaio de Freitas, Cristina Rodrigues dos Santos Barbosa, Dárcio Luiz de Sousa Júnior, Abolghasem Siyadatpanah, Morteza Nejat, Polrat Wilairatana, Henrique Douglas Melo Coutinho, Francisco Assis Bezerra da Cunha. (2021). Evaluation of Benzaldehyde as an Antibiotic Modulator and Its Toxic Effect against Drosophila melanogaster. Molecules, 26(18), p.5570. https://doi.org/10.3390/molecules26185570.

4. Carlos Alonso Leite dos Santos, Raimundo Luiz da Silva Pereira, Luís Pereira-de-Morais, George Joaquim Garcia Santos, Henrique Douglas Melo Coutinho, Francisco Assis Bezerra da Cunha, Fabiola Fernandes Galvão Rodrigues, Dárcio Luiz de Sousa Júnior, Julio Cesar Silva. (2025). Antibacterial activity of ethanolic extract of Ocimum gratissimum L. (BASIL) and its toxicity against Drosophila melanogaster. Pharmacological Research - Natural Products, 7, p.100212. https://doi.org/10.1016/j.prenap.2025.100212.

5. Ana Luíza A.R. Martin, Raimundo Luiz Silva Pereira, Janaína Esmeraldo Rocha, Pablo A.M. Farias, Thiago S. Freitas, Francisco Rodrigo de Lemos Caldas, Fernando G. Figueredo, Nadghia Figueiredo Leite Sampaio, Cícera Datiane de Morais Oliveira-Tintino, Saulo Relison Tintino, Gabriel Costa A. da Hora, Maria Carolina Pacheco Lima, Irwin Rose A. de Menezes, Diogo T. Carvalho, Henrique D.M. Coutinho, Marta M.F. Fonteles. (2024). Unlocking bacterial defense: Exploring the potent inhibition of NorA efflux pump by coumarin derivatives in Staphylococcus aureus. Microbial Pathogenesis, 190, p.106608. https://doi.org/10.1016/j.micpath.2024.106608.

6. Benneth Ben-Azu, Elisabetta C. del Re, Jared VanderZwaag, Micaël Carrier, Matcheri Keshavan, Mohammadparsa Khakpour, Marie-Ève Tremblay. (2023). Emerging epigenetic dynamics in gut-microglia brain axis: experimental and clinical implications for accelerated brain aging in schizophrenia. Frontiers in Cellular Neuroscience, 17 https://doi.org/10.3389/fncel.2023.1139357.

7. Fernando Gomes Figueredo, Rodrigo Emmanuel L. T. Parente, Maynara Rodrigues Cavalcante-Figueredo, Jakson Gomes Figueiredo, Raimundo Luiz Pereira da Silva, Edinardo Fagner Ferreira Matias, Tania Maria Sarmento Silva, Celso Amorim Camara, Cícera Datiane de Morais Oliveira-Tintino, Saulo Relison Tintino, Henrique Douglas Melo Coutinho, Marta Maria de Franca Fonteles. (2021). Inhibition of Staphylococcus aureus TetK and MsrA efflux pumps by hydroxyamines derived from lapachol and norlachol. Journal of Bioenergetics and Biomembranes, 53(2), p.149. https://doi.org/10.1007/s10863-021-09885-5.

8. Hélida Maravilha Dantas e Sousa Almeida, Lara Bianca Soares Brandão, Thamara Rodrigues de Melo, Sávio Benvindo Ferreira. (2022). Anti-Bacterial Perspective of Non-Antibiotic Drugs. The 2nd International Electronic Conference on Antibiotics—Drugs for Superbugs: Antibiotic Discovery, Modes of Action and Mechanisms of Resistance. , p.22. https://doi.org/10.3390/eca2022-12701.

9. Wanessa Santana, Simone S. C. de Oliveira, Mariana H. Ramos, André L. S. Santos, Silvio S. Dolabella, Eliana B. Souto, Patrícia Severino, Sona Jain. (2021). Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre‐Clinical to Clinical Findings. Chemistry & Biodiversity, 18(9) https://doi.org/10.1002/cbdv.202100336.

10. Maria Milene Costa da Silva, José Bezerra de Araújo Neto, Antonia Thassya Lucas dos Santos, Cícera Datiane de Morais Oliveira-Tintino, Ana Carolina Justino de Araújo, Priscilla Ramos Freitas, Luiz Everson da Silva, Wanderlei do Amaral, Cícero Deschamps, Francisco Roberto de Azevedo, Clara Mariana Gonçalves Lima, Nadezhda Golubkina, João Tavares Calixto-Júnior, Jaime Ribeiro-Filho, Henrique Douglas Melo Coutinho, Gianluca Caruso, Saulo Relison Tintino. (2023). Antibiotic-Potentiating Activity of the Schinus terebinthifolius Raddi Essential Oil against MDR Bacterial Strains. Plants, 12(8), p.1587. https://doi.org/10.3390/plants12081587.

11. Vladimir S. Kurćubić, Svetlana V. Raketić, Jelena M. Mašković, Pavle Z. Mašković, Luka V. Kurćubić, Volker Heinz, Igor B. Tomasevic. (2023). Evaluation of Antimicrobial Activity of Kitaibelia vitifolia Extract against Proven Antibiotic-Susceptible and Multidrug-Resistant (MDR) Strains of Bacteria of Clinical Origin. Plants, 12(18), p.3236. https://doi.org/10.3390/plants12183236.

Dimensions

PlumX

Visitas a la página del resumen del artículo

1578

Descargas

Los datos de descargas todavía no están disponibles.

Licencia

Derechos de autor 2019 Revista Colombiana de Ciencias Químico-Farmacéuticas

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia  autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.

Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13